Savitha Subramanian
Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1215012034
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,413 of the $71,479 with a category attached, or 67.7%. Abbott accounts for 60.1% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $25,413, 2.7 times the $9,559 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $562.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$43K
- Ionis Pharmaceuticals, Inc.$14K
- Boehringer Ingelheim$9K
- Amarin Pharma, Inc.$2K
- Akcea Therapeutics, Inc.$2K
- Kaneka Medical America LLC$1K
- plus $296 from 5 others
Across 20 payments — averaging $3227.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$64K
- Eli Lilly$313
What the payments were for
- Consulting fees$48,41368%
- Speaking & faculty fees$10,68715%
- Travel & lodging$7,95711%
- Food & beverage$4,3586%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 97 | $42,927 |
| Ionis Pharmaceuticals, Inc. | 20 | $14,119 |
| Boehringer Ingelheim | 1 | $9,452 |
| Amarin Pharma, Inc. | 1 | $1,870 |
| Akcea Therapeutics, Inc. | 1 | $1,580 |
| Kaneka Medical America LLC | 1 | $1,235 |
| Regeneron | 1 | $107 |
| Amgen | 1 | $65 |
| Novo Nordisk | 2 | $65 |
| Bayer | 1 | $36 |
| Novartis | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$19,137
- FreeStyle Libre$17,030
- OLEZARSEN$13,354
- JARDIANCE$9,452
- FreeStyle Libre Pro$4,038
- Vascepa$1,870
- LIPOSORBER$1,235
- PRALUENT$107
How this compares
$71,479 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 126 | $127,670 |
| JardianceEmpagliflozin | 57 | $78,914 |
| OzempicSemaglutide | 36 | $74,260 |
| Praluent PenAlirocumab | 35 | $42,162 |
| MounjaroTirzepatide | 31 | $38,889 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $38,722 |
| TrulicityDulaglutide | 24 | $33,635 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $14,440 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $9,224 |
| NexletolBempedoic Acid | 13 | $7,806 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $7,209 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,115 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $6,812 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 26 | $5,669 |
| Novolog FlexpenInsulin Aspart | 26 | $5,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $9,452 | $78,91457 claims |
| Novo NordiskOzempic, Novolog | $65 | $76,84547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Seattle
- Irl HirschSeattle$192K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- William HagopianSeattle$30K
- Mahnaz MellatiSeattle$28K
- Alan ChaitSeattle$21K
- Jose GarciaSeattle$12K
- Carla GreenbaumSeattle$7K
- Tracy TyleeSeattle$7K
- Asha PathakSeattle$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.